Parkinson's Disease: Global Market Value To Decrease By 2019 As Loss Of Patent Halts Pharmaceutical Development: GBI Research

Published: Dec 17, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK (GBI Research), 17 December 2013 -- Due to upcoming patent expirations for four high-profile drugs, the global Parkinson’s Disease (PD) market is expected to decline from $3.4 billion in 2012 to $2.9 billion by 2019, at a negative Compound Annual Growth Rate (CAGR) of 2.3%, says a new report from business intelligence provider GBI Research.

The company’s latest report* states that PD drugs, such as Azilect (rasagiline mesylate), Stalevo (levodopa, carbidopa, entacapone) and Comtan (entacapone), will lose their patents by the end of the forecast period. Generic alternatives for these treatments have already been approved, which will result in further market competition.

Additionally, the loss of patent for Mirapex (pramipexole dihydrochloride) and Exelon (rivastigmine tartrate) in 2010 and 2012 will continue to halt future PD market growth.

Angel Wong, Analyst for GBI Research, says: “In the most likely scenario, late-stage pipeline drugs, including Rytary, safinamide and pimavanserin, are expected to be approved and launched in the market within the forecast period. However, this won’t be significant enough to diminish the impact of generic erosion.”

Furthermore, with the majority of existing PD drugs focusing on symptomatic relief, a disease-modifying treatment remains an urgent unmet need in the PD market. The current pipeline consists of 21% neuroprotective targets, while 87% are currently in discovery and preclinical development. The remaining molecules are distributed in Phase I and Phase II. “These targets represent innovation in the pipeline and could become effective disease-modifying treatments in the future. However, the development of such medication faces several challenges, including the absence of neuroprotective candidates in the late pipeline and the need for a reliable biomarker that can accelerate such development,” the analyst concludes.

*Parkinson’s Disease Therapeutics Market to 2019 - Pipeline Shows Shift towards Long Term Disease Management

This report provides in-depth analysis of the drugs available for the treatment of Parkinson’s Disease, covering their safety, efficacy, treatment patterns, and strengths/weaknesses, as well as a heat map comparing drugs in terms of safety and efficacy. It gives multi-scenario market forecast data to 2019, taking into account the introduction of new drugs, the expiration of key patents, and changes in disease epidemiology across the US, Canada, France, Germany, Italy, Spain, the UK and Japan.

This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GBI Research’s team of industry experts.


GBI Research is a market-leading provider of business intelligence reports, offering actionable data and forecasts based on the insights of key industry leaders to ensure you stay up-to-date with the latest emerging trends in your markets.

For more information, please contact our Press Office on +44 (0)1204 543 528 or at

Help employers find you! Check out all the jobs and post your resume.

Back to news